Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fatty liver disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: Fatty liver disease. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2014-003422-41 Sponsor Protocol Number: Rifa-Stea Start Date*: 2014-10-13
    Sponsor Name:Oulu University Hospital, Department of Internal Medicine
    Full Title: The effects of PXR activation on hepatic fat content
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004871 10024681 Liver fatty change LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-008275-34 Sponsor Protocol Number: Edi-Omeg3-08001 Start Date*: 2009-08-20
    Sponsor Name:NHS Lothian [...]
    1. NHS Lothian
    2. University of Edinburgh
    Full Title: The Effect of Omega-3 Fatty Acids on Non-Alcoholic Fatty Liver Disease
    Medical condition: Non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015703-13 Sponsor Protocol Number: InReTel Start Date*: 2009-12-11
    Sponsor Name:Klinik für Innere Medizin II der Klinikum Chemnitz gGmbH
    Full Title: The influence of Telmisartan on insulin resistance and fatty liver in patients suffer from hypertension
    Medical condition: Influence of Telmisartan on insulin resistance, hypertension, non-alcoholic fatty liver
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020772 Hypertension LLT
    12.0 10052066 Metabolic syndrome LLT
    12.0 10022489 Insulin resistance LLT
    12.0 10016261 Fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003766-26 Sponsor Protocol Number: 25-12-59 Start Date*: 2009-10-12
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease
    Medical condition: Non alcoholic fatty liver disease (NAFLD). This fatty liver disease may progress to a chronic condition that sometimes deteriorates further to cirrhosis and even liver carcinoma. To date there is n...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006677-26 Sponsor Protocol Number: 68797373 Start Date*: 2022-06-22
    Sponsor Name:Maastricht University
    Full Title: Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease
    Medical condition: Healthy volunteers (non-alcoholic fatty liver disease)
    Disease: Version SOC Term Classification Code Term Level
    25.0 10024581 - Lipid metabolism and deposit disorders NEC 10029530 Non-alcoholic fatty liver PT
    25.0 10024581 - Lipid metabolism and deposit disorders NEC 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005531-28 Sponsor Protocol Number: Urso in Obese Start Date*: 2008-04-03
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery
    Medical condition: Patients with morbid obesity (MB) are investigated. MB is very frequently (90%) associated with non-alcoholic fatty liver disease (NAFLD) comprising a spectrum reaching from steatosis (NAFL) over s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003168-37 Sponsor Protocol Number: CAIN457ADE15 Start Date*: 2019-12-04
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, multicenter, 24-week study of subcutaneous secukinumab to assess anti-interleukin-17A treatment in plaque psoriasis patients with coexisting non-alcoholic fatty liver di...
    Medical condition: plaque psoriasis with coexisting non-alcoholic fatty liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021515-17 Sponsor Protocol Number: N/A Start Date*: 2010-09-30
    Sponsor Name:Imperial College London
    Full Title: RiFL: Rifaxamin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?
    Medical condition: Non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053219 non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000813-37 Sponsor Protocol Number: OCABSGS Start Date*: 2012-05-16
    Sponsor Name:Sahlgrenska Academy
    Full Title: Effects of obeticholic acid on hepatic fatty acid/triglyceride metabolism and hepatobiliary detoxification/elimination in morbidly obese and gallstone patients.
    Medical condition: Fatty liver disease, morbid obesity, gallstone disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004605-38 Sponsor Protocol Number: NUC-4/NAS Start Date*: 2015-02-11
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver di...
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001975-36 Sponsor Protocol Number: 201200197536 Start Date*: 2012-05-24
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Evaluation on the efficacy of docosahexaenoic acid for the treatment of nonalcoholic fatty liver disease in children
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015166-62 Sponsor Protocol Number: EME-08/43/15 Start Date*: 2010-11-16
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: A randomised controlled trial of Losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.
    Medical condition: Fibrosis in patients with non-alcoholic steatohepatitis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000152-19 Sponsor Protocol Number: 1 Start Date*: 2022-02-24
    Sponsor Name:Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)
    Full Title: Control strategies and pharmacogenetic study for the personalized treatment of fatty liver associated with metabolic dysfunction in patients with prediabetes.
    Medical condition: Metabolic Associated Fatty Liver Disease with prediabetes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004141-24 Sponsor Protocol Number: 228763 Start Date*: 2018-01-26
    Sponsor Name:Brighton and Sussex University Hospitals NHS Trus
    Full Title: A phase IV, open-label pilot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised backgro...
    Medical condition: Non-alcoholic fatty liver disease in people living with well-controlled HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver PT
    20.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003164-21 Sponsor Protocol Number: 652-2-203 Start Date*: 2015-01-05
    Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc
    Full Title: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021368-13 Sponsor Protocol Number: MTQ-LD-001 Start Date*: 2010-09-28
    Sponsor Name:Antipodean Pharmaceuticals
    Full Title: A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants with Raised Liver Enzymes due to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Medical condition: Raised Liver Enzymes due to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002253-29 Sponsor Protocol Number: CEC-11/NAS Start Date*: 2022-03-08
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of ZED1227 capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD) wi...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005187-63 Sponsor Protocol Number: FM101-CTP2-001 Start Date*: 2021-04-14
    Sponsor Name:Future Medicine Co., Ltd.
    Full Title: A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Medical condition: Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    22.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-017080-41 Sponsor Protocol Number: GWMD09112 Start Date*: 2010-04-19
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease.
    Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004402-55 Sponsor Protocol Number: 6344-001A Start Date*: 2020-11-09
    Sponsor Name:Baxter Healthcare Corporation
    Full Title: A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (lip...
    Medical condition: Essential Fatty Acid Deficiency (EFAD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10015486 Essential fatty acid deficiency LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:19:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA